We develop and produce highly specialized targeted investor and business development conferences exclusively for the biopharmaceutical and life sciences industries.
With over 20 years’ experience connecting leaders of innovative biotech companies with key stakeholders, investors and advisors, we create ideal environments to examine and address opportunities and challenges in today’s biotech industry.
I’ve been working with the biotechnology industry for the past 20 years. As an outside supporter of the industry, my goal has been to develop programs and services that facilitate the success of this industry and the companies that comprise it. With that as a constant, about three years ago I launched annual CEO gatherings in the US and Europe with the overarching theme of identifying and discussing success strategies for “The Purposeful (biotech) CEO.”
The year ahead in biotech is primed to be a stock-pickers' market. Fundamental growth among commercial biotechs in the U.S. is forecast to be similar to 2017, while non-U.S. stocks are poised for a slowdown. In this regard, Gilead is set for another challenging year, while Amgen and Vertex could surprise on commercial execution. The top potential clinical catalyst plays across BI's coverage include Celgene, Biogen, Incyte and Exelixis.
In the big picture, political threats to drug pricing may be reignited after a subdued 2017. Payer-driven pressure is expected to remain opportunistically rampant and pressure recent launches. It's unclear if 2018 will wake up M&A after a sleepy 2017, but licensing deals should carry on strong.